Why treating parasitic infections is one of the most difficult challenges in modern medicine

Health · Published 3 October 2026 Swipe more like this →

In short: Antiparasitic drugs combat everything from helminths to protozoa, yet they remain notoriously difficult to develop. Because parasites often share biological similarities with their human hosts, early treatments were frequently toxic. Today, the field faces a dual crisis of rising drug resistance and a historical lack of investment in new therapies.

Antiparasitics represent a vital class of antimicrobial medication designed to destroy or inhibit the growth of organisms like amoeba, fungi, and worms. Unlike broad-spectrum options that target a wide array of infections, most of these drugs are highly specific, effective only against a limited range of parasites. This precision is necessary because the fundamental challenge in parasitology is distinguishing the parasite from the host. Historically, this difficulty meant that early attempts at treatment were often ineffective or dangerously toxic to the patient.

The development of new antiparasitics has historically lagged behind other medical fields. Between 1975 and 1999, only 13 of the 1,300 new drugs approved were antiparasitics, a disparity driven by a lack of financial incentives for diseases primarily affecting low-income populations. This stagnation prompted a shift toward public-private partnerships, such as those supported by the Bill and Melinda Gates Foundation, which helped accelerate the development of 20 new agents between 2000 and 2005. Researchers are now exploring innovative avenues, including metal-containing compounds and triazolopyrimidines, to bypass existing resistance and reduce side effects.

Drug repurposing has emerged as a pragmatic strategy to overcome these hurdles. By applying existing medications—such as using cancer drugs or antibiotics for parasitic infections—scientists can bypass the lengthy and expensive early-stage safety testing required for new compounds. Meanwhile, in veterinary medicine, resistance is becoming a pressing concern. Despite this, surveys suggest that environmental impact and drug resistance remain low priorities for many practitioners, who instead focus on ease of administration and client preference. As parasitic diseases continue to impact an estimated 2 billion people globally, the need for better stewardship and novel therapeutic targets remains urgent.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• How a 1975 discovery became the world's most versatile weapon against parasitic worms
• Why parasites are the most successful and misunderstood organisms on our planet
• A Nobel-winning parasite drug started out protecting dogs from heartworm
• Could a parasitic worm actually be the key to curing modern diseases?
• Parasites are not just distant threats; they are complex organisms living off our biology.
• Antisense therapy uses synthetic genetic code to silence disease-causing messages within our cells.
• Antimicrobials are not just one thing: they are a vast, complex chemical arsenal.
• Are your antiseptics actually helping, or are they training bacteria to become stronger?
• Antifungal medicines stop fungal growth, but they must be used with careful medical guidance.
• Why antiviral drugs are fundamentally different from the antibiotics in your medicine cabinet
• Why the most effective medical antidotes are not always the safest clinical choice
• A potent antimalarial compound derived from wormwood is now revealing surprising new medical potential.

More in Drugs and medication · More in Health · Latest · A–Z · All topics